Table 3.

Oncolytic vaccinia viruses tested in current clinical trials.

Oncolytic vaccinia virus	Tumor Selectivity	Route of Administration	Combination	Indication	Phases	NCT Number	Sponsor/Collaborators	Status
GL-ONC1	generating interruptions in the thymidine kinase, F14.5L and hemagglutinin genes.	Intraperitoneal injection	Bevacizumab	Recurrent or Refractory Ovarian Cancer	Phase 1, Phase 2	NCT02759588	Genelux Corporation	Recruiting
		Intraperitoneal Injection	none	Advanced Peritoneal Carcinomatosis	Phase 1|Phase 2	NCT01443260		Completed
		Intravenous Injection	none	Advanced Solid Tumors	Phase 1	NCT00794131		Completed
		Intravenous Injection	Cisplatin, Radiotherapy	Head & Neck Cancer	Phase 1	NCT01584284		Completed
		Intravenous Injection	Surgery	Solid Organ Cancers Undergoing Surgery	Phase 1	NCT02714374	Kaitlyn Kell  intravenousy, MD,Genelux Corporation, University of California, San Diego	Active, not recruiting
Pexa-Vec (JX-594)	Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF	Intravenous Injection	none	Peritoneal Carcinomatosis of Ovarian Cancer Origin	Phase 2	NCT02017678	Andrea McCart, Ontario Institute for Cancer Research, Mount Sinai Hospital, Canada	Withdrawn
		Intratumoral Injection	none	Liver Cancer (Failed Sorafenib)	Phase 2	NCT01387555	Jennerex Biotherapeutics	Completed
		Intratumoral Injection	none	Primary or Metastatic Hepatic Carcinoma	Phase 1	NCT00629759	Jennerex Biotherapeutics, Green Cross Corporation	Completed
		Intravenous Injection	none	Refractory Solid Tumors	Phase 1	NCT00625456	Jennerex Biotherapeutics, SillaJen, Inc.	Completed
		Intratumoral Injection	none	Refractory Solid Tumors in Pediatric Patients	Phase 1	NCT01169584	Jennerex Biotherapeutics, SillaJen, Inc.	Completed
		Intravenous Injection	Irinotecan	Metastatic, Refractory Colorectal Carcinoma	Phase 1, Phase 2	NCT01394939	Jennerex Biotherapeutics, Transgene, SillaJen, Inc.	Completed
		Intratumoral Injection	none	Malignant Melanoma	Phase 1, Phase 2	NCT00429312	Jennerex Biotherapeutics	Completed
		Intratumoral Injection	none	Unresectable Primary Hepatocellular Carcinoma	Phase 2	NCT00554372	Jennerex Biotherapeutics, SillaJen, Inc.	Completed
		Intravenous Injection	Durvalumab	Refractory Colorectal Cancer	Phase 1/2	NCT03206073	National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC)	Recruiting
		Intratumoral Injection	Ipilimumab	Metastatic / Advanced Solid Tumors	Phase 1	NCT02977156	Centre Leon Berard|Transgene	Recruiting
		Intravenous Injection/ Intratumoral Injection	REGN2810 (anti-PD-1)	Renal Cell Carcinoma	Phase 1	NCT03294083	SillaJen, Inc., Regeneron Pharmaceuticals	Recruiting
			Sorafenib	Hepatocellular Carcinoma	Phase 3	NCT02562755	SillaJen, Inc.	Active, not recruiting
ASP9801	Deletion of VGF and O1L gene	Intratumoral Injection	none	Advanced Metastatic Solid Tumors	Phase 1	NCT03954067	-Astellas Pharma Global Development, Inc., -Astellas Pharma Inc	Recruiting
TBio-6517 (TAK-605)	Unknown	Intratumoral Injection	Pembrolizumab	Solid tumors	Phase 1/2	NCT04301011		Recruiting
RGV004	Deletion to thymidine kinase gene	Intratumoral Injection	None	Refractory/Relapsed B-cell Lymphoma	Phase 1	NCT04887025	-Second Affiliated Hospital, School of Medicine, Zhejiang University -Hangzhou Rongu Biotechnology Co., Ltd.	Not yet recruiting
T601	-Deletion to thymidine kinase gene -Deletion to Ribonucleotide Reductase gene	N/A	5-FC	Solid tumors	Phase 1/2	NCT04226066	Tasly Tianjin Biopharmaceutical Co., Ltd.	Recruiting
TG6002 (VV TK-RR-FCU1)	-Deletion to thymidine kinase gene -Deletion to Ribonucleotide Reductase gene	Intrahepatic arterial administration	5-FC	Metastatic colorectal cancer	Phase 1/2	NCT04194034	Transgene	Recruiting
		Intravenous injection	5-FC	Advanced gastrointestinal tumor	Phase 1/2	NCT03724071	Transgene	Recruiting